Weave Communications Forecasts Q1 Revenue of $64.6M; Launches NDA Workflow with Parexel
Weave Communications is set to report Q1 2026 revenue of $64.57 million and a loss of $0.10 per share, with full-year revenue estimates trimmed to $274.64 million from $274.87 million. The company also launched an AI-native NDA submission workflow in partnership with Parexel to cover the full regulatory lifecycle.
1. Q1 2026 Earnings Preview and Estimate Revisions
Weave Communications is scheduled to release Q1 2026 results on April 30, with analysts forecasting $64.57 million in revenue and a loss of $0.10 per share. Full-year 2026 revenue estimates have been revised down slightly to $274.64 million, while 2027 revenue projections ticked up to $312.38 million. Earnings per share forecasts improved to a -$0.37 loss for 2026 and -$0.31 for 2027. In the prior quarter, the company posted $63.40 million in revenue and a -$0.02 EPS, both of which beat expectations, though the stock fell 4.91% post-announcement.
2. Launch of NDA Workflow with Parexel Partnership
Weave Bio extended its AI-native regulatory automation platform by adding support for New Drug Application (NDA) submissions in collaboration with Parexel. This partnership leverages Parexel’s 40 years of regulatory experience to enhance the platform’s coverage across the full drug development regulatory lifecycle, potentially accelerating submission timelines and expanding Weave’s addressable market.